ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy
Key result
Review outlines shared domains and differing management strategies between ACC/AHA and ESC DAPT guidelines.
Why the study?
Both the ACC/AHA and ESC recently released updated recommendations on DAPT in CAD, prompting a review to delineate common domains, consistent messages, and differences across the Atlantic.
Key Points
- This research examines the differences between ACC/AHA and ESC guidelines on dual antiplatelet therapy.
- Comparative analysis of ACC/AHA and ESC guidelines
- Evaluation of recommendations regarding clopidogrel and aspirin use
- Assessment of risk factors influencing dual antiplatelet therapy
- ACC/AHA recommends dual antiplatelet therapy for a longer duration in specific populations
- ESC guidelines emphasize risk stratification before prescribing therapy
- Differences in guidelines may lead to varying clinical practices across regions
Structured PICO
P
Population
Patients with coronary artery disease (CAD)
E
Exposure
Dual antiplatelet therapy (DAPT) guideline recommendations (ACC/AHA and ESC)
This review highlights the similarities and differences between the ACC/AHA and ESC guidelines regarding the duration and selection of dual antiplatelet therapy in patients with coronary artery disease.
Ask about this paper
Answers are grounded in this paper and cite their sources.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“By putting the document together, we found that on the two sides of the pond, actually there are more similarities than differences.”
Implication
Clinicians should note regional DAPT guideline differences to avoid inconsistent care; leaves open the need for harmonized recommendations.
Abstract
Dual antiplatelet therapy (DAPT) is the cornerstone of pharmacological treatment aimed at preventing the atherothrombotic complications in patients with a variety of coronary artery disease (CAD) manifestations. Prescribers of DAPT are confronted with a number of challenges that include selecting the appropriate P2Y12 inhibitor and determining the optimal duration of DAPT with the scope of minimizing the risk of ischemic and bleeding complications in light of each patient's clinical characteristic and circumstance. Recently, a guideline writing committee from the American College of Cardiology/American Heart Association (ACC/AHA) and a task force from the European Society of Cardiology (ESC) released their respective focused update recommendations on "Duration of DAPT in Patients with CAD" (ACC/AHA) and "DAPT in CAD" (ESC). This paper aims to review the ACC/AHA and ESC updates for DAPT to delineate common domains, consistent messages, and differences in recommended management strategies across the Atlantic.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Capodanno et al. (2018) conducted a review in Coronary artery disease (CAD). ACC/AHA and ESC guidelines on Dual Antiplatelet Therapy was evaluated. A review of the ACC/AHA and ESC updates for dual antiplatelet therapy delineates common domains, consistent messages, and differences in recommended management strategies.